Cipla, Unitaid ink pact to reduce price of HIV drug
Drug major Cipla and Switzerland-based Unitaid have inked a pact under which the Indian drug major would reduce price of a combination therapy which prevents infections in people living with HIV.
Under the agreement, Cipla will reduce the ceiling price of the medicine (Q-TIB) by more than 30 percent from USD 3 to USD 1.99 per person, per month, for all public-sector procurers in lowand middle-income countries.
The agreement would lead to reduction in price of Q-TIB, as governments and international funding bodies procure large quantities for their HIV treatment programmes.
The combination therapy is a once-daily pill that protects in three ways against TB, the leading cause of death among people with HIV, and against other life-threatening bacterial, and protozoan infections.